New AI-Discovered Natural Alternative to Ozempic

Stanford Researchers Discover Natural Molecule That Mimics Ozempic Without Key Side Effects

Scientists at Stanford Medicine have identified a naturally occurring molecule that suppresses appetite and reduces body weight in animals, offering a potential alternative to popular weight-loss drugs like Ozempic (semaglutide) without several of their common side effects. The molecule, named BRP, acts through a distinct but related metabolic pathway, targeting the brain’s hypothalamus to regulate appetite and metabolism more precisely.

How BRP Works Differently From Ozempic

Ozempic and similar GLP-1 receptor agonists, such as Wegovy and Mounjaro, work by mimicking the hormone GLP-1, which influences multiple bodily systems. While effective for weight loss, these drugs often cause side effects like nausea, constipation, and muscle loss due to their broad effects on the gut, pancreas, and other tissues.

In contrast, BRP appears to act primarily in the hypothalamus, the brain region responsible for hunger and energy balance. According to the research, this targeted approach may avoid the digestive and muscular side effects associated with current weight-loss medications.

“The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas, and other tissues. That’s why Ozempic has widespread effects, including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.”

Katrin Svensson, PhD, assistant professor of pathology at Stanford Medicine

Discovery Process: AI and Prohormone Research

The molecule was identified using artificial intelligence to analyze a class of proteins called prohormones, which are biologically inert until cleaved into smaller, active peptides. Each prohormone can produce multiple functional peptides, making manual analysis time-consuming. AI helped researchers sift through dozens of candidates to pinpoint BRP as a promising appetite-suppressing agent.

The study, published on March 5, 2026, in Nature, was led by senior author Katrin Svensson and lead author Laetitia Coassolo, PhD, a senior research scientist at Stanford Medicine. The findings suggest that BRP could offer a more refined approach to weight management by focusing on the brain’s hunger signals rather than the broader physiological effects of GLP-1 drugs.

Animal Studies Show Promise, Human Trials Planned

In preclinical tests, BRP reduced appetite and body weight in animals without causing nausea, constipation, or significant muscle loss—common issues with GLP-1 medications. The molecule also activated different neurons in the brain compared to semaglutide, reinforcing its potential as a distinct therapeutic option.

Svensson has co-founded a company to advance BRP into human clinical trials, though no timeline for these studies has been publicly announced. If successful, the molecule could provide an alternative for patients seeking weight-loss treatments with fewer side effects.

Expert Perspectives on BRP’s Potential

Giles Yeo, a professor of molecular neuroendocrinology at the UK Medical Research Council’s Metabolic Diseases Unit, explained to DW that current weight-loss drugs primarily affect the hindbrain, which regulates feelings of fullness and discomfort. While these drugs also influence the hypothalamus, their broader effects contribute to side effects like nausea.

“The hypothalamus is the hunger sensor,” Yeo said. “It operates from dealing with starvation to no starvation. It’s trying to detect within your body: Am I starving or not? How hungry am I? The hindbrain does something different. It targets the visceral effect. It targets fullness, uncomfortably full: ‘Oh my God—I am Christmas full! I’m so full, I feel like puking.’”

BRP’s focus on the hypothalamus could help patients achieve weight loss without the extreme fullness or digestive discomfort associated with existing treatments.

Limitations and Next Steps

While the preclinical results are promising, BRP’s safety and efficacy in humans remain unproven. Clinical trials will be necessary to determine whether the molecule’s benefits translate from animal models to human patients. The long-term effects of BRP on metabolism and overall health are not yet understood.

The discovery highlights the potential of AI-driven research in accelerating drug development. By narrowing down candidates from complex biological datasets, researchers can identify novel compounds with greater precision, potentially leading to more targeted and tolerable therapies.

Broader Implications for Obesity Treatment

Obesity remains a global health challenge, with current pharmacological treatments offering significant benefits but also notable drawbacks. Drugs like Ozempic and Wegovy have transformed weight-loss therapy, but their side effects and high cost limit accessibility for many patients. A molecule like BRP, if proven effective in humans, could expand treatment options for those who struggle with obesity but cannot tolerate existing medications.

The research also underscores the importance of exploring natural compounds as sources of new therapies. While synthetic drugs dominate the market, naturally occurring molecules like BRP may offer unique advantages, such as fewer off-target effects or improved tolerability.

As the field of weight-loss pharmacology continues to evolve, discoveries like BRP could help refine treatment approaches, moving beyond broad-spectrum drugs to more precise interventions tailored to individual patient needs.